Journal article icon

Journal article

Comprehensive characterization of single-cell full-length isoforms in human and mouse with long-read sequencing

Abstract:
Single cell analysis of cancer cell transcriptome may shed a completely new light on cancer-associated thrombosis (CAT). CAT causes morbid, and sometimes lethal complications in certain human cancers known to be associated with high risk of venous thromboembolism (VTE), pulmonary embolism (PE) or arterial thromboembolism (ATE), all of which worsen patients’ prognosis. How active cancers drive these processes has long evaded scrutiny. While “unspecific” microenvironmental effects and consequences of patient care (e.g., chemotherapy) have been implicated in pathogenesis of CAT, it has also been suggested that oncogenic pathways driven by either genetic (mutations), or epigenetic (methylation) events may influence the coagulant phenotype of cancer cells and stroma, and thereby modulate the VTE/PE risk. Consequently, the spectrum of driver events and their downstream effector mechanisms may, to some extent, explain the heterogeneity of CAT manifestations between cancer types, molecular subtypes, and individual cases, with thrombosis-promoting, or -protective mutations. Understanding this molecular causation is important if rationally designed countermeasures were to be deployed to mitigate the clinical impact of CAT in individual cancer patients. In this regard, multi-omic analysis of human cancers, especially at a single cell level, has brought a new meaning to concepts of cellular heterogeneity, plasticity, and multicellular complexity of the tumour microenvironment, with profound and still relatively unexplored implications for the pathogenesis of CAT. Indeed, cancers may contain molecularly distinct cellular subpopulations, or dynamic epigenetic states associated with different profiles of coagulant activity. In this article we discuss some of the relevant lessons from the single cell “omics” and how they could unlock new potential mechanisms through which cancer driving oncogenic lesions may modulate CAT, with possible consequences for patient stratification, care, and outcomes
Publication status:
Published
Peer review status:
Peer reviewed

Actions

Access Document

Publisher copy:
10.1186/s13059-021-02525-6

Authors

More by this author
Role:
Author
ORCID:
0000-0003-3420-3685
More by this author
Role:
Author
ORCID:
0000-0002-6302-4857
More by this author
Role:
Author
ORCID:
0000-0002-4493-306X
More by this author
Role:
Author
ORCID:
0000-0002-5142-7886
More by this author
Role:
Author
ORCID:
0000-0002-2229-8106


More from this funder
Funder identifier:
10.13039/100014989
Grant:
2018-182819 and 2019-002443
More from this funder
Funder identifier:
10.13039/501100000923
Grant:
200102903
More from this funder
Funder identifier:
10.13039/501100000925
Grant:
1143163 and 1104924


Publisher:
BioMed Central
Journal:
Genome Biology More from this journal
Volume:
22
Issue:
1
Pages:
310-310
Article number:
310
Publication date:
2021-11-11
DOI:
EISSN:
1474-760X
ISSN:
1474-7596


Language:
English
Keywords:
Pubs id:
1211078
Local pid:
pubs:1211078
Source identifiers:
W3214478476
Deposit date:
2026-04-08
ARK identifier:
This ORA record was generated from metadata provided by an external service. It has not been edited by the ORA Team.

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP